Supplementary Material: Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Takahiro Wakasaki, Ryuji Yasumatsu, Muneyuki Masuda, Toranoshin Takeuchi, Tomomi Manako, Mioko Matsuo, Rina Jiromaru, Ryutaro Uchi, Noritaka Komune, Teppei Noda and Takashi Nakagawa

Table S1. Profiles of adverse events appearing during salvage chemotherapy following nivolumab.

| Category                  | Number of Events(all n = 39) | Number of Events(PC n = 25) | Number of Events(S1 n = 14) |
|---------------------------|-------------------------------|-----------------------------|-----------------------------|
|                           | Total (n) (§) | Grade 3/4 (n) (§) | Total (n) (§) | Grade 3/4 (n) (§) | Total (n) (§) | Grade 3/4 (n) (§) | Total (n) (§) | Grade 3/4 (n) (§) |
| Any                       | 32 82.1 | 17 43.6 | 24 96.0 | 16 64.0 | 8 57.1 | 1 2.4 |
| Skin disorder             | 13 33.3 | 5 12.8 | 13 52.0 | 5 20.0 | 0 0.0 | 0 0.0 |
| Perionychia               | 3 7.7 | 1 2.6 | 3 12.0 | 1 4.0 | 0 0.0 | 0 0.0 |
| Gastrointestinal          | 2 5.1 | 0 0.0 | 1 4.0 | 0 0.0 | 1 7.1 | 0 0.0 |
| Hepatobiliary             | 3 7.7 | 0 0.0 | 2 8.0 | 0 0.0 | 1 7.1 | 0 0.0 |
| Interstitial pneumonitis  | 5 12.8 | 1 2.6 | 4 16.0 | 1 4.0 | 1 7.1 | 0 0.0 |
| Fatigue                   | 4 10.3 | 1 2.6 | 3 12.0 | 1 4.0 | 1 7.1 | 0 0.0 |
| Fever                     | 3 7.7 | 0 0.0 | 1 4.0 | 0 0.0 | 2 14.3 | 0 0.0 |
| Peripheral neuropathy     | 1 2.6 | 0 0.0 | 1 4.0 | 0 0.0 | 0 0.0 | 0 0.0 |
| Leukopenia                | 20 51.3 | 16 41.0 | 16 64.0 | 15 60.0 | 4 28.6 | 1 2.4 |
| Neutropenia               | 15 38.5 | 10 25.6 | 14 56.0 | 10 40.0 | 1 7.1 | 0 0.0 |
| Hypomagnesia              | 4 10.3 | 3 7.7 | 4 16.0 | 3 12.0 | 0 0.0 | 0 0.0 |
| Others                    | 6 15.4 | 2 5.1 | 3 12.0 | 2 8.0 | 3 21.4 | 0 0.0 |

AEs, adverse events; S1, tegafur-gimestat-otastat potassium; SCT, salvage chemotherapy.
Table S2. Summary of the previous definitive therapies and the administration lines of SCT.

| Pt | SCT | Gender | Age | Primary Site     | Previous Definitive Therapies | Administration Lines of SCT |
|----|-----|--------|-----|------------------|------------------------------|----------------------------|
| 1  | PC  | F      | 75  | Oral             | Ope, RT                      | 4                          |
| 2  | PC  | M      | 66  | Oral             | IC, Ope, CRT                 | 2                          |
| 3  | PC  | F      | 33  | Oral             | Ope, CRT                     | 2                          |
| 4  | PC  | M      | 60  | Oral             | Ope, RT                      | 3                          |
| 5  | PC  | M      | 63  | Oral             | IC, Ope, CRT                 | 3                          |
| 6  | PC  | M      | 71  | Oral             | Ope, CRT                     | 2                          |
| 7  | PC  | F      | 77  | Oral             | Ope, RT                      | 3                          |
| 8  | PC  | M      | 56  | Nasopharynx      | IC + CRT                     | 2                          |
| 9  | PC  | M      | 51  | Nasopharynx      | CRT                          | 2                          |
| 10 | PC  | M      | 74  | Oropharynx       | CRT                          | 2                          |
| 11 | PC  | M      | 47  | Oropharynx       | Ope, CRT                     | 2                          |
| 12 | PC  | M      | 62  | Oropharynx       | CRT                          | 2                          |
| 13 | PC  | M      | 63  | Hypopharynx      | IC, CRT                      | 3                          |
| 14 | PC  | M      | 65  | Hypopharynx      | CRT                          | 2                          |
| 15 | PC  | M      | 75  | Hypopharynx      | Ope, CRT                     | 2                          |
| 16 | PC  | M      | 54  | Hypopharynx      | CRT, Ope                     | 2                          |
| 17 | PC  | M      | 68  | Hypopharynx      | CRT                          | 2                          |
| 18 | PC  | M      | 64  | Sinonasal tract  | CRT                          | 3                          |
| 19 | PC  | M      | 73  | Sinonasal tract  | IC, Ope, CRT                 | 2                          |
| 20 | PC  | M      | 69  | Sinonasal tract  | IC, Ope, CRT                 | 2                          |
| 21 | PC  | M      | 66  | Sinonasal tract  | Ope, CRT                     | 2                          |
| 22 | PC  | M      | 56  | Larynx           | Ope, CRT                     | 3                          |
| 23 | PC  | M      | 69  | Larynx           | Ope                          | 3                          |
| 24 | PC  | F      | 45  | Others           | Ope                          | 2                          |
| 25 | PC  | F      | 78  | Others           | Ope, CRT                     | 3                          |
| 26 | S1  | M      | 71  | Oral             | Ope, CRT                     | 2                          |
| 27 | S1  | M      | 64  | Oral             | Ope, CRT                     | 2                          |
| 28 | S1  | F      | 40  | Nasopharynx      | IC, CRT                      | 5                          |
| 29 | S1  | M      | 59  | Nasopharynx      | None                         | 3                          |
| 30 | S1  | M      | 67  | Oropharynx       | CRT                          | 3                          |
| 31 | S1  | M      | 71  | Oropharynx       | IC, CRT, Ope                 | 3                          |
| 32 | S1  | M      | 59  | Oropharynx       | CRT, Ope                     | 2                          |
| 33 | S1  | M      | 68  | Oropharynx       | Ope, CRT                     | 4                          |
Pt, patient; SCT, salvage chemotherapy; Ope, operation; IC, induction chemotherapy; CRT, chemoradiotherapy.